1 October 2020 - Phase 1 clinical trial is now enrolling patients with blood cancers.
The U.S. Food and Drug Administration has granted Fast Track designation to a novel “switchable” CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.
The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia.